Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Karsten Lyby
Novo Nordisk
9Publications
5H-index
240Citations
Publications 9
Newest
Published on May 16, 2019in Clinical Pharmacokinectics 4.68
Inge B. Halberg1
Estimated H-index: 1
,
Karsten Lyby5
Estimated H-index: 5
+ 3 AuthorsEric Zijlstra10
Estimated H-index: 10
Background Oral insulin 338 is a novel tablet formulation of a long-acting basal insulin. This randomised, open-label, four-period crossover trial investigated the effect of timing of food intake on the single-dose pharmacokinetic properties of oral insulin 338.
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 24.54
Inge B. Halberg1
Estimated H-index: 1
(Novo Nordisk),
Karsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
+ 3 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Summary Background Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. Methods This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequatel...
Published on Mar 1, 2011in Diabetes Care 15.27
Kåre I. Birkeland43
Estimated H-index: 43
(University of Bergen),
Philip Home54
Estimated H-index: 54
(Newcastle University)
+ 8 AuthorsJ. Hans DeVries45
Estimated H-index: 45
(UvA: University of Amsterdam)
OBJECTIVE Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes. RESEARCH DESIGN AND METHODS In this 16-week, randomized, open-label trial, participants (mean: 45.8 years old, A1C 8.4%, fasting plasma glucose [FPG] 9.9 mmol/L, BMI 26.9 kg/m 2 ) rece...
Published on Mar 1, 2011in Diabetes & Metabolism 4.01
G. Charpentier47
Estimated H-index: 47
,
P. Fontaine25
Estimated H-index: 25
+ 11 AuthorsJohan Jendle14
Estimated H-index: 14
Introduction L’insuline Degludec (IDeg) est un nouvel analogue de l’insuline qui forme des multi-hexameres solubles apres injection sous-cutanee (SC), ce qui lui confere une duree d’action ultra longue. Materiels et methodes Essai ouvert de phase 2 de 16 semaines randomise, en groupes paralleles, portant sur l’efficacite et l’innocuite de l’IDeg chez des diabetiques de type 1. Ils se sont injecte en SC l’IDeg (n = 59), ou de l’insuline Glargine (IGlar, n = 59) une fois par jour, le soir, en plus...
Published on Jan 1, 2011
Kåre I. Birkeland43
Estimated H-index: 43
,
Philip Home54
Estimated H-index: 54
+ 8 AuthorsJ. Hans DeVries45
Estimated H-index: 45
OBJECTIVE—Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes. RESEARCH DESIGN AND METHODS—In this 16-week, randomized, open-label trial, participants (mean: 45.8 years old, A1C 8.4%, fasting plasma glucose [FPG] 9.9 mmol/L, BMI 26.9 kg/m 2 ) rece...
Published on Apr 1, 2007in Fertility and Sterility 5.41
Johan Smitz62
Estimated H-index: 62
(Vrije Universiteit Brussel),
Helen-Mary Picton1
Estimated H-index: 1
(LGI: Leeds General Infirmary)
+ 7 AuthorsChristian Grøndahl16
Estimated H-index: 16
(Novo Nordisk)
Objective To evaluate the safety of applying follicular-fluid meiosis-activating sterol (FF-MAS) in vitro to immature human oocytes. Design Phase I bicenter, randomized, parallel-group, controlled, partially blinded trial. Setting Third-level referral academic centers, including reproductive biology and genetics laboratories. Patients Endocrinologically normal women with a medical indication for IVF or intracytoplasmic sperm injection, or healthy volunteers. Intervention(s) Subjects were randomi...
Published on Oct 1, 2005in Fertility and Sterility 5.41
Anne Loft23
Estimated H-index: 23
(Copenhagen University Hospital),
Søren Ziebe24
Estimated H-index: 24
(Copenhagen University Hospital)
+ 7 AuthorsKarsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
Objective To evaluate the effect of adding follicular-fluid meiosis-activating sterol (FF-MAS) in a novel 0.2% recombinant human albumin–based formulation to cumulus-enclosed oocytes on chromosomal status and development of pre-embryos. Design Multicenter, prospective, randomized, open (double-blind for vehicle and FF-MAS groups), four parallel groups, controlled trial. Setting Four public IVF clinics in Denmark. Patient(s) Two hundred eighteen women undergoing IVF donated 483 oocytes. Intervent...
Published on Dec 1, 2000in Epilepsy Research 2.18
Peter Uldall29
Estimated H-index: 29
,
Christine Bulteau22
Estimated H-index: 22
+ 2 AuthorsKarsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
Abstract Tiagabine, a specific γ-aminobutyric acid-uptake inhibitor, has been shown to be reasonably well tolerated and efficacious as adjunctive treatment for partial seizures in adults and is now being investigated in children. This 4-month, single-blind study evaluated the tolerability, safety and preliminary efficacy of ascending doses (0.25–1.5 mg/kg/day) of tiagabine add-on therapy in 52 children over the age of 2 years with different syndromes of refractory epilepsy. Adverse events, mostl...
Published on Mar 1, 1998in Epilepsy Research 2.18
Reetta Kälviäinen45
Estimated H-index: 45
,
Martin J. Brodie66
Estimated H-index: 66
(Western Infirmary)
+ 3 AuthorsKarsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
Abstract In a multicentre, double-blind, parallel-group, placebo-controlled trial, a three-times daily regimen of tiagabine was evaluated as add-on therapy in 154 adult patients with refractory partial seizures. A total of 77 patients were randomised to treatment in each arm. Tiagabine HCl was titrated from an initial dose of 12–30 mg/day over 4 weeks. During the 12-week fixed-dose period, there was a significant reduction in the median 4-weekly seizure rate for all partial seizures and simple p...
1